ELAN Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $1.371 billion, a 15% increase year-over-year; 10% organic constant currency growth driven by 2% price and 8% volume.
Adjusted EBITDA: $334 million, up 21% year-over-year.
Adjusted EPS: $0.40, an 8% increase year-over-year.
Gross Margin: 57%, a slight decrease of 40 basis points due to inflation and product mix.
Net Debt: $3.3 billion with a net leverage ratio of 3.5x, improved from previous guidance of 3.1x to 3.3x.

2. Strategic Updates and Business Highlights

Innovation Performance: Generated $287 million in revenue from innovation products, raising the full-year innovation target to $1.2 billion.
Market Share Gains: Significant growth in U.S. pet health categories, particularly in parasiticides and dermatology, with Zenrelia and Credelio Quattro leading the way.
Corporate Accounts: Increased engagement with corporate accounts, contributing to a 12% growth in corporate accounts.
Product Launches: Successful launch trajectory for Zenrelia and upcoming launch of Befrena, with strong veterinarian support and initial feedback.
Elanco Ascend Initiative: Ongoing efforts to enhance operational efficiency and productivity, with over 5,000 projects logged.

3. Forward Guidance and Outlook

Full-Year Guidance: Organic constant currency growth revised to 5% to 7% (previously 4% to 6%); adjusted EBITDA guidance raised to $975 million to $1.005 billion; adjusted EPS guidance increased to $1.03 to $1.09.
Second Quarter Guidance: Expected revenue of $1.3 billion to $1.325 billion, with organic constant currency growth of 4% to 6%.
U.S. Pet Health Growth: Anticipated acceleration to high single-digit to low double-digit growth in the second half of the year.

4. Bad News, Challenges, or Points of Concern

Label Restrictions: Continued FDA dialogue regarding Zenrelia's label, with additional studies requested, which could delay potential label improvements.
Competitive Pressures: Heightened competition from generics and other market entrants, particularly in the pet health sector.
Economic Headwinds: Potential consumer budget constraints could impact vet visit volumes, although not factored into current guidance.
Gross Margin Pressures: Anticipated decline in gross margin due to inflation and inventory costs, although expected recovery in the latter half of the year.

5. Notable Q&A Insights

U.S. Pet Health Performance: Initial slow growth due to winter weather, but significant recovery noted in March and April, driven by strong demand for Zenrelia and Quattro.
Corporate Accounts Strategy: Focus on value-based approaches to corporate accounts, leveraging strong product performance to drive adoption.
Zenrelia's Success: Despite label restrictions, strong market performance attributed to product efficacy and growing adoption in clinics.
Befrena Launch: Anticipated ramp-up in the second half of the year, with positive feedback from veterinarians.
Capital Deployment: Prioritizing organic investments and debt reduction, with potential for M&A opportunities in the future once leverage targets are met.

Overall, Elanco reported a strong quarter with robust growth driven by innovation and market share gains, while also navigating challenges related to competition and regulatory scrutiny. The company remains optimistic about its strategic direction and growth potential in the animal health sector.

ELAN — Elanco Animal Health Incorporated